SCHEMBL3402617

SCHEMBL3402617

COC(=O)c1sc(Cl)nc1-c1cn(C)nn1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 5/20 0.37
LMNA P02545 1/20 0.36
TRPM8 Q7Z2W7 1/20 0.35
NPC1 O15118 1/20 0.33
POLB P06746 1/20 0.33
RAB9A P51151 1/20 0.33
MAPT P10636 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
GAA P10253 1/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 1/20 0.33
KDM4A O75164 1/20 0.33
KDM5C P41229 1/20 0.33
KDM4C Q9H3R0 1/20 0.33
KDM2A Q9Y2K7 1/20 0.33
KDM3A Q9Y4C1 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13070801 0.84 ALDH1A1 (0.40) BRD4TRPM8POLBSMN1; SMN2ALDH1A1
SCHEMBL3406917 0.73 ALDH1A1 (0.46) LMNANPC1POLBRAB9AMAPT
SCHEMBL13993307 0.72 ALDH1A1 (0.37) LMNANPC1POLBRAB9AMAPT
SCHEMBL3405606 0.71 ECE1 (0.46) LMNANPC1POLBRAB9AMAPT
SCHEMBL509631 0.71 ADORA2A (0.37) LMNANPC1POLBRAB9AMAPT
SCHEMBL3402237 0.71 LMNA (0.44) LMNATRPM8NPC1POLBRAB9A
SCHEMBL1552538 0.71 LMNA (0.36) LMNANPC1POLBRAB9ASMN1; SMN2
SCHEMBL11278098 0.71 LMNA (0.64) LMNATRPM8SMN1; SMN2ALDH1A1MEN1
SCHEMBL11289442 0.71 MAPT (0.52) LMNANPC1RAB9AMAPTSMN1; SMN2
SCHEMBL3406312 0.70 ALDH1A1 (0.41) LMNANPC1POLBRAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
EP-2158199-B1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2010-11-17 EP disclosed
WO-2008152418-A1 PIPERIDINE COMPOUNDS AND USES THEREOF ASTRAZENECA AB (SE) 2008-12-18 WO disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 ASTRAZENECA AB (SE) 2008-12-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312255-A1 PIPERDINE COMPOUNDS AND USES THEREOF-911 NISCH, PIR, QDPR BRD4 3457/4885LMNA 2265/4885TRPM8 2191/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.